[Expression and clinical significance of miR-21 in diffuse large B cell lymphoma].
This study was aimed to investigate the expression of microRNA-21 and its correlation with PTEN in diffuse large B cell lymphoma (DLBCL) paraffin-embedded tissues, and evaluate its potential relevance with clinical characteristics. The expression levels of miR-21 in 26 primary DLBCL and 10 normal lymph node tissue specimens were examined by real-time polymerase chain reaction. The expression of PTEN was detected by immunohistochemical staining. The results indicated that the expression of miR-21 was significantly higher in tumor tissues [6.586(1.10,38.22)] than that in normal tissues [0.791 (0.35,2.87)] (P < 0.05). Among 26 patients with DLBCL the expression of PTEN protein was positive in 6 patients (23%), and was negative in 20 patients (77%). In patients with DLBCL, the expression level of miR-21 was negatively correlated with the level of PTEN protein. The high expression of miR-21 was positively correlated with the level of serum LDH. The expression level of miR-21 in patients with Ann Arbor III-IV stage was obviously higher than that of patients with Ann Arbor I-II stage, but did not correlate with the subtype of patients in clinic (P > 0.05). It is concluded that the expression of miR-21 is high in DLBCL and its overexpression may be related with poor prognosis of DLCBL. These findings suggest that PTEN is possibly one of the targets of miR-21 in DLBCL.
Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Chun-Hong
CH
Li
Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China. E-mail: florai@sina.com.
Rong
R
Fu
Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Yi-Hao
YH
Wang
Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Wen-Jing
WJ
Song
Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Er-Bao
EB
Ruan
Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Wen
W
Qu
Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Hua-Quan
HQ
Wang
Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Guo-Jin
GJ
Wang
Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Jia
J
Song
Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Xiao-Ming
XM
Wang
Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Yu-Hong
YH
Wu
Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Li-Min
LM
Xing
Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Hong
H
Liu
Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Li-Juan
LJ
Li
Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Jing
J
Guan
Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China. E-mail: shaozonghong@sina.com.
Zong-Hong
ZH
Shao
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000378:metabolism* / Q000473:pathology; D008297:Male; D035683:MicroRNAs / Q000378:metabolism*; D008875:Middle Aged; D051059:PTEN Phosphohydrolase / Q000378:metabolism; D060888:Real-Time Polymerase Chain Reaction
C524940:MIRN21 microRNA, human; D035683:MicroRNAs; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human